Study Dismisses Concerns that Psoriasis Treatment Could Trigger IBD

Study Dismisses Concerns that Psoriasis Treatment Could Trigger IBD
Taltz (ixekizumab), an approved antibody treatment for plaque psoriasis, targets a cytokine that is thought to play a role in the development of inflammatory bowel disease (IBD). That connection has caused concerns that administration of the drug might increase occurrence of IBDs in patients with psoriasis. So, Eli Lilly and Company, the maker of Taltz, conducted a study to determine  if there was a significant correlation. Results showed that rates of new IBD cases were observed in less than 1 percent of the psoriasis patients receiving Taltz. They reported that flares of pre-existing disease also were rare. Titled “
Subscribe or to access all post and page content.